Prescribing shift for Pfizer’s Paxlovid expands access but draws questions
Pharmaceutical Technology
JULY 20, 2022
However, the American Medical Association (AMA) released a statement warning that while most patients benefit from Paxlovid, it is not for everyone. The US FDA has not announced any updates to Lagevrio’s label.
Let's personalize your content